SEARCH

SEARCH BY CITATION

References

  • 1
    Bernard C. Introduction à l’étude de la mèdecine expérimentale. Paris: Baillère, 1865.
  • 2
    Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis 1967; 20: 63748.
  • 3
    Huth EJ. Needed: review articles with more scientific rigour. Ann Intern Med 1987; 106: 4701.
  • 4
    Grilli R, Magrini N, Penna A, Mura G, Liberati A. Practice guidelines developed by specialty societies: the need for a critical appraisal. Lancet 2000; 355: 1036.
  • 5
    Moore TC. Deadly Medicine. New York: Simon & Schuster, 1995.
  • 6
    Kahan JP, Neu CR, Hamons GT, Illman BJ. The Decision to Initiate Clinical Trials of Current Medical Practices. Santa Monica, CA: Rand Corporation, 1985.
  • 7
    Freiman JA, Chalmers TC, Smith H, Kuebler RR. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial: survey of 71 negative trials. New Engl J Med 1978; 299: 6904.
  • 8
    Lachin JM. Introduction to sample size determination and power analysis for clinical trials. Control Clin Trials 1981; 2: 93113.
  • 9
    Garret AD. Therapeutic equivalence: fallacies and falsification. Stat Med 2003; 22: 74162.
  • 10
    Boissel JP, Collet JP, Moleur P, Haugh M. Surrogate end-points: a basis for a rational approach. Eur J Clin Pharmacol 1992; 43: 23544.
  • 11
    Buyse M, Molenberghs G. The validation of surrogate end-points in randomized experiments. Biometrics 1998; 54: 101429.
  • 12
    Yusuf S, Collins R, Peto R. Why do we need some large, simple randomized trials? Stat Med 1984; 3: 40920.
  • 13
    ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; ii: 34960.
  • 14
    The EMIP Group. Pre-hospital thrombolytic therapy in patients with suspected acute myocardial infarction. N Engl J Med 1993; 329: 3839.
  • 15
    Moseley JB, O'Malley K, Petersen NJ et al. A controlled trial of arthroscopic surgery for osteoarthritis of the knee. N Engl J Med 2002; 347: 818.
  • 16
    Cochran WG, Cox GM. Experimental Designs. New York: Wiley & Sons, 1957.
  • 17
    Armitage P. Statistical Methods in Medical Research. Oxford: Blackwell, 1971.
  • 18
    Collet J-P, Boissel J-P and the VALIDATA Group. Sick population-treated population: the need for a better definition. Eur J Clin Pharmacol 1991; 41: 48991.
  • 19
    Boissel JP, Peyrieux JC and the EPSIM Research Group. Sub-grouping of post myocardial infarction patients according to their one-year death risk. Eur Heart J 1987; 8: 127280.
  • 20
    Boissel JP, Leizorovicz A, Picolet H, Ducruet T and the APSI investigators. Efficacy of acebutolol after acute myocardial infarction (The APSI Trial). Am J Cardiol 1990; 66: 2431.
  • 21
    The EPSIM Research Group. Controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction. N Engl J Med 1982; 307: 7018.
  • 22
    Boissel JP, Collet JP, Lièvre M, Girard P. An effect model for the assessment of drug benefit: example of antiarrhythmic drugs in postmyocardial infarction patients. J Cardiovasc Pharmacol 1993; 22: 35663.
  • 23
    Boissel J-P, Gueyffier F, Haugh M. Response to ‘Inclusion of Women and Minorities in Clinical Trials and the NIH Revitalization Act of 1993 – the perspective of NIH Clinical Trialists’. Control Clin Trials 1995; 16: 2868.
  • 24
    Boissel JP. Individualizing aspirin therapy for prevention of cardiovascular events. JAMA 1998; 280: 194950.
  • 25
    Boissel JP, Gueyffier F, Cucherat M, Bricca G. Pharmacogenetics and responders to a therapy: theoretical background and practical problems. Clin Chem Lab Med 2003; 41: 56472.
  • 26
    Meinert CL. Quality assurance in clinical trials. In: BoisselJP, KlimtCR, eds. Multicenter Controlled Trials: Principles and Problems. Paris: Inserm, 1979; 12330.
  • 27
    Meier P. Terminating a trial – the ethical problem. Clin Pharmacol Therap 1979; 25: 63340.
  • 28
    Canner PL. Monitoring clinical trial data for evidence of adverse or beneficial treatment. In: BoisselJP, KlimtCR, eds. Multicenter Controlled Trials: Principles and Problems. Paris: Inserm, 1979; 13150.
  • 29
    Armitage P. Sequential Medical Trials. Oxford: Blackwell, 1975.
  • 30
    Pocock SJ. Group sequential methods in the design and analysis of clinical trials. Biometrika 1977; 64: 1919.
  • 31
    DeMets DL, Lan KK. Interim analysis: the alpha spending function approach. Stat Med 1994; 13: 134152.
  • 32
    DeMets DL, Ware JH. Asymmetric group sequential boundaries for monitoring clinical trials. Biometrika 1982; 69: 6613.
  • 33
    Friedman LM, Furberg CD, DeMets DL. Fundamentals of Clinical Trials. Boston: John Wright PSG, 1981.
  • 34
    Pocock SJ. Clinical Trials: A Practical Approach. Chichester: Wiley & Sons, 1990.